Acquired Ichthyosis Triggered by an Osseous Hemangiopericytoma: A Case Report and Review of the Literature

Ichthyoses are a heterogeneous group of cutaneous keratinization disorders that can be congenital or acquired. Apart from neoplastic disorders, the acquired form of ichthyosis (AI) has been associated with a variety of diseases including infections, autoimmune/inflammatory and endocrine/metabolic diseases as well as nutritional conditions, medications and others. However, malignancy accounts for half of the reported cases, most commonly including lymphoproliferative disorders. We present a case of AI as a paraneoplastic skin manifestation of a primary, osseous hemangiopericytoma (HP) accompanied by multiple liver metastases. We also review the literature and discuss the necessity of investigating underlying diseases, especially malignancy, when adult-onset ichthyosis arises

New developments in our understanding of acne pathogenesis and treatment

Interest in sebaceous gland physiology and its diseases is rapidly increasing. We provide a summarized update of the current knowledge of the pathobiology of acne vulgaris and new treatment concepts that have emerged in the last 3 years (2005-2008). We have tried to answer questions arising from the exploration of sebaceous gland biology, hormonal factors, hyperkeratinization, role of bacteria, sebum, nutrition, cytokines and toll-like receptors (TLRs). Sebaceous glands play an important role as active participants in the innate immunity of the skin. They produce neuropeptides, excrete antimicrobial peptides and exhibit characteristics of stem cells. Androgens affect sebocytes and infundibular keratinocytes in a complex manner influencing cellular differentiation, proliferation, lipogenesis and comedogenesis. Retention hyperkeratosis in closed comedones and inflammatory papules is attributable to a disorder of terminal keratinocyte differentiation. Propionibacterium acnes, by acting on TLR-2, may stimulate the secretion of cytokines, such as interleukin (IL)-6 and IL-8 by follicular keratinocytes and IL-8 and -12 in macrophages, giving rise to inflammation. Certain P. acnes species may induce an immunological reaction by stimulating the production of sebocyte and keratinocyte antimicrobial peptides, which play an important role in the innate immunity of the follicle. Qualitative changes of sebum lipids induce alteration of keratinocyte differentiation and induce IL-1 secretion, contributing to the development of follicular hyperkeratosis. High glycemic load food and milk may induce increased tissue levels of 5 alpha-dihydrotestosterone. These new aspects of acne pathogenesis lead to the considerations of possible customized therapeutic regimens. Current research is expected to lead to innovative treatments in the near future.Zouboulis CC, 2008, EXP GERONTOL, V43, P986, DOI 10.1016/j.exger.2008.09.001Nakatsuji T, 2008, J INVEST DERMATOL, V128, P2451, DOI 10.1038/jid.2008.117Melnik B, 2008, J DTSCH DERMATOL GES, V6, P721, DOI 10.1111/j.1610-0387.2008.06822.xPalomba S, 2008, CURR OPIN OBSTET GYN, V20, P364Lee DY, 2008, J INVEST DERMATOL, V128, P1863, DOI 10.1038/sj.jid.5701235Zouboulis CC, 2008, EXP DERMATOL, V17, P542, DOI 10.1111/j.1600-0625.2008.00725.xDel Rosso JQ, 2008, J DRUGS DERMATOL, V7, pS2Melnik BC, 2008, BRIT J DERMATOL, V158, P1397, DOI 10.1111/j.1365-2133.2008.08559.xHong I, 2008, J INVEST DERMATOL, V128, P1266, DOI 10.1038/sj.jid.5701134Lo Celso C, 2008, STEM CELLS, V26, P1241, DOI 10.1634/stemcells.2007-0651Pelle E, 2008, J INVEST DERMATOL, V128, P1280, DOI 10.1038/sj.jid.5701160Fuchs E, 2008, GENE DEV, V22, P976, DOI 10.1101/gad.1645908Koltun W, 2008, CONTRACEPTION, V77, P249, DOI 10.1016/j.contraception.2007.11.003Smith RN, 2008, J DERMATOL SCI, V50, P41, DOI 10.1016/j.jdermsci.2007.11.005Fenner JA, 2008, PEDIATR DERMATOL, V25, P179, DOI 10.1111/j.1525-1470.2008.00628.xTreloar V, 2008, J AM ACAD DERMATOL, V58, P175, DOI 10.1016/j.jaad.2007.10.017GANCEVICIENE R, 2008, BRIT J DERMATOL, V160, P345Danby FW, 2008, CLIN DERMATOL, V26, P93, DOI 10.1016/j.clindermatol.2007.09.018Jarrousse V, 2007, ARCH DERMATOL RES, V299, P441, DOI 10.1007/s00403-007-0774-5Russell LE, 2007, EXP DERMATOL, V16, P844, DOI 10.1111/j.1600-0625.2007.00612.xCharakida A, 2007, BRIT J DERMATOL, V157, P569, DOI 10.1111/j.1365-2133.2007.08083.xKurokawa I, 2007, BRIT J DERMATOL, V157, P415, DOI 10.1111/j.1365-2133.2007.08047.xVerfaille CJ, 2007, BRIT J DERMATOL, V157, P122, DOI 10.1111/j.1365-2133.2007.07896.xGanceviciene R, 2007, EXP DERMATOL, V16, P547, DOI 10.1111/j.1600-0625.2007.00565.xHarrison WJ, 2007, J INVEST DERMATOL, V127, P1309, DOI 10.1038/sj.jid.5700743Hana A, 2007, LIFE SCI, V80, P2214, DOI 10.1016/j.lfs.2007.02.007Thielitz A, 2007, J INVEST DERMATOL, V127, P1042, DOI 10.1038/sj.jid.5700439Stecova J, 2007, PHARM RES, V24, P991, DOI 10.1007/s11095-006-9225-9Clarke SB, 2007, DERMATOL CLIN, V25, P137, DOI 10.1016/j.det.2007.01.004Kurokawa I, 2007, J CUTAN PATHOL, V34, P338, DOI 10.1111/j.1600-0560.2006.00619.xMakrantonaki E, 2007, BRIT J DERMATOL, V156, P428, DOI 10.1111/j.1365-2133.2006.07671.xZiegler CG, 2007, HORM METAB RES, V39, P106, DOI 10.1055/s-2007-961809Krause K, 2007, HORM METAB RES, V39, P166, DOI 10.1055/s-2007-961811Seiffert K, 2007, HORM METAB RES, V39, P141, DOI 10.1055/s-2007-961814Fimmel S, 2007, HORM METAB RES, V39, P149, DOI 10.1055/s-2007-961815LUCKY AW, 2007, J DRUGS DERMATOL, V6, P981Danby FW, 2007, J AM ACAD DERMATOL, V56, P164, DOI 10.1016/j.jaad.2006.04.022Ottaviani M, 2006, J INVEST DERMATOL, V126, P2430, DOI 10.1038/sj.jid.5700434Chen WC, 2006, J INVEST DERMATOL, V126, P2332, DOI 10.1038/sj.jid.5700442Gan L, 2006, IMMUNOL RES, V35, P295, DOI 10.1385/IR:35:3:295Trivedi NR, 2006, J INVEST DERMATOL, V126, P2002, DOI 10.1038/sj.jid.5700336Grando SA, 2006, J INVEST DERMATOL, V126, P1948, DOI 10.1038/sj.jid.5700151Layton AM, 2006, J EUR ACAD DERMATOL, V20, P773, DOI 10.1111/j.1468-3083.2006.01671.xNagy I, 2006, MICROBES INFECT, V8, P2195, DOI 10.1016/j.micinf.2006.04.001Pasquali R, 2006, EUR J ENDOCRINOL, V154, P763, DOI 10.1530/eje.1.02156Suzuki N, 2006, SCIENCE, V311, P1927, DOI 10.1126/science.1124256Schroder JM, 2006, CELL MOL LIFE SCI, V63, P469, DOI 10.1007/s00018-005-5364-0Zhang L, 2006, PEPTIDES, V27, P413, DOI 10.1016/j.peptides.2005.05.030Alestas T, 2006, J MOL MED-JMM, V84, P75, DOI 10.1007/s00109-005-0715-8MELO MN, 2006, RECENT PAT ANTIINFEC, V1, P201Oeff MK, 2006, DERMATOLOGY, V213, P266, DOI 10.1159/000095056MITKOV M, 2006, EUR J OBSTET GYN R B, V126, P93Ganceviciene R, 2006, DERMATOLOGY, V213, P270, DOI 10.1159/000095058IRAJI F, 2006, DERMATOL ONLINE J, V12, P26Youn SW, 2005, BRIT J DERMATOL, V153, P919, DOI 10.1111/j.1365-2133.2005.06794.xPapakonstantinou E, 2005, J INVEST DERMATOL, V125, P673, DOI 10.1111/j.0022-202X.2005.23848.xOhnuma K, 2005, MOL CELL BIOL, V25, P7743, DOI 10.1128/MCB.25.17.7743-7757.2005Georgel P, 2005, INFECT IMMUN, V73, P4512, DOI 10.1128/IAI.73.8.4512-4521.2005Nagy I, 2005, J INVEST DERMATOL, V124, P931, DOI 10.1111/j.0022-202X.2005.23705.xHoyt G, 2005, BRIT J NUTR, V93, P175, DOI 10.1079/BJN20041304Adebamowo CA, 2005, J AM ACAD DERMATOL, V52, P207, DOI 10.1016/j.jaad.2004.08.007McDowell A, 2005, J CLIN MICROBIOL, V43, P326, DOI 10.1128/JCM.43.1.326-334.2005Kurzen H, 2004, J INVEST DERMATOL, V123, P937, DOI 10.1111/j.0022-202X.2004.23425.xZouboulis CC, 2004, CLIN DERMATOL, V22, P360, DOI 10.1016/j.clindermatol.2004.03.004Namazi MR, 2004, INT J DERMATOL, V43, P701Smolinski KN, 2004, CURR OPIN PEDIATR, V16, P385Bruggemann H, 2004, SCIENCE, V305, P671Reinel D, 2004, HAUTARZT, V55, P143, DOI 10.1007/s00105-003-0680-5BALANA ME, 2004, J DRUGS DERMATOL, V3, P287Burkhart CN, 2003, INT J DERMATOL, V42, P925Niemann C, 2003, P NATL ACAD SCI USA, V100, P11873, DOI 10.1073/pnas.1834202100Chen WC, 2003, J INVEST DERMATOL, V121, P441Rosignoli C, 2003, EXP DERMATOL, V12, P480Ansorge S, 2003, Z NATURFORSCH C, V58, P580Thiboutot D, 2003, J INVEST DERMATOL, V120, P905Zhang L, 2003, ANN NY ACAD SCI, V994, P154Koreck A, 2003, DERMATOLOGY, V206, P96, DOI 10.1159/000068476Jain A, 2003, PHYTOMEDICINE, V10, P34, DOI 10.1078/094471103321648638Milani M, 2003, CURR MED RES OPIN, V19, P135, DOI 10.1185/030079903125001523Huang QH, 2002, NEUROSCI LETT, V334, P186Toyoda M, 2002, EUR J DERMATOL, V12, P422Kim J, 2002, J IMMUNOL, V169, P1535Toyoda M, 2002, EXP DERMATOL, V11, P241Zouboulis CC, 2002, P NATL ACAD SCI USA, V99, P7148, DOI 10.1073/pnas.102180999Bohm M, 2002, J INVEST DERMATOL, V118, P533Nakamura M, 2001, EXP DERMATOL, V10, P369Chronnell CMT, 2001, J INVEST DERMATOL, V117, P1120Sato T, 2001, J INVEST DERMATOL, V117, P965Kono M, 2001, FASEB J, V15, P2297Freedberg IM, 2001, J INVEST DERMATOL, V116, P633Lomri A, 2001, J BONE MINER RES, V16, P705Ghazizadeh S, 2001, EMBO J, V20, P1215, DOI 10.1093/emboj/20.6.1215Zouboulis CC, 2001, DERMATOLOGY, V203, P277Thiboutot D, 2000, J INVEST DERMATOL, V115, P614Taylor G, 2000, CELL, V102, P451Deplewski D, 2000, ENDOCR REV, V21, P363Zouboulis CC, 1999, J INVEST DERMATOL, V113, P1011Munro CS, 1998, LANCET, V352, P704Scholzen T, 1998, EXP DERMATOL, V7, P81Zouboulis CC, 1998, DERMATOLOGY, V196, P21Thiboutot DM, 1997, BRIT J DERMATOL, V136, P166Bernerd F, 1996, ARCH DERMATOL RES, V288, P586Guy R, 1996, J INVEST DERMATOL, V106, P454Hughes BR, 1996, BRIT J DERMATOL, V134, P247KOLDOVSKY O, 1995, VITAM HORM, V50, P77ZOUBOULIS CC, 1994, EXP DERMATOL, V3, P151AKAMATSU H, 1992, J INVEST DERMATOL, V99, P509PASSI S, 1991, J DERMATOL SCI, V2, P84ZOUBOULIS CC, 1991, SKIN PHARMACOL, V4, P74XIA LQ, 1989, J INVEST DERMATOL, V93, P315THODY AJ, 1989, PHYSIOL REV, V69, P383KUROKAWA I, 1988, J INVEST DERMATOL, V91, P566DOWNING DT, 1986, J AM ACAD DERMATOL, V14, P221DARLING JAB, 1974, J ENDOCRINOL, V62, P291KNUTSON DD, 1974, J INVEST DERMATOL, V62, P288KLIGMAN AM, 1970, ARCH DERMATOL, V102, P2675

Topical prebiotics/postbiotics and PRURISCORE validation in atopic dermatitis. International study of 396 patients

Aim: To investigate the efficacy and tolerability of a cream (Rilastil Xerolact PB) containing a mixture of prebiotics and postbiotics, and to validate the PRURISCORE itch scale in the management of atopic dermatitis. Methods: The study is based on 396 subjects of both sexes in three age groups (i.e., infants, children, adults) suffering from mild/moderate Atopic Dermatitis, recruited from 8 European countries and followed for 3 months. Results: The product demonstrated good efficacy combined with good/very good tolerability in all age groups. In particular, SCORAD, PRURISCORE and IGA scores decreased significantly over the course of the study. The PRURISCORE was preferred to VAS by the vast majority of patients. Conclusion: Even though the role of prebiotics and postbiotics was not formally demonstrated since these substances were part of a complex formulation, it can be reasonably stated that prebiotics and postbiotics have safety and standardization features that probiotics do not have. In addition they are authorized by regulatory authorities, whereas topical probiotics are not